Navigation Links
Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
Date:5/25/2010

BASKING RIDGE, N.J., May 25 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, today announced issuance of another key patent related to their proprietary technology.  This new patent includes coverage for RB007, the modulator or active control component of Regado's innovative product candidates, the REG1 and REG2 anticoagulation systems.  The allowed claims in U.S. Patent No. 7,723,315 broadly cover modulators that are capable of binding to certain blood coagulation Factor IX/IXa inhibiting aptamers and include both composition of matter and methods of use claims.  The term for this patent extends to April 2025.

ABOUT REGADO BIOSCIENCES

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems.  Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent.  This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care setting, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control.  Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.

ABOUT REG1 and REG2  

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
2. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
3. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
4. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
5. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
6. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
7. Regado Biosciences Establishes Medical Advisory Board
8. Regado Biosciences Expands Medical Advisory Board
9. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
10. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
11. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Biovista Inc. freut sich, ... 2015 bekanntgeben zu können. Hierbei handelt es sich ... Biovista unterstützt mit seiner Möglichkeit der Analyse ... Krankheiten als denen, für die ein Medikament ursprünglich ... Team bei der Wylder Nation Foundation bei der ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... Services Staff members will be attending Pharma Ed Resources upcoming educational seminar ... group of industry leading speakers, this timely conference will provide Updates & Case ...
(Date:9/2/2015)... Diego, CA (PRWEB) , ... September 02, 2015 ... ... troubleshooting faults in manufacturing equipment, to creating professional commercial video content, to analysis ... detailed views of fascinating events that go by too quickly to process with ...
(Date:9/1/2015)... Swecure, ein Biotechnologieunternehmen, ... Entwicklung neuartiger Therapien für Störungen des Immunsystems ... konzentriert, erhält vom US Patent and Trademark ... patentiert wird. Das Medikament basiert auf einem ... und Entzündungen vorbeugt.   Das Medikament, ...
Breaking Biology Technology:Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2
... October 5 , - A New Miniaturized PCR ... Price of QuanTyper(TM) Without Loss of Performance, - ... AlphaHelix (Ticker: ALPH) has in a very ... for lower,instrument prices. This was made possible through know-how obtained during,the ...
... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported ... bavituximab in combination with carboplatin and paclitaxel in patients ... reported from the initial cohort of 21 patients in ... patients with locally advanced or metastatic NSCLC achieved an ...
... ... Global packaging specialist,Sepha, says the increased pressure to reduce costs and ... and blister-scanning technologies. While blisterpacks offer pharmaceutical companies a simple ... often makes it difficult to either test for leaks or recover ...
Cached Biology Technology:AlphaHelix Presents AmpXpress(TM) at the BIOTECHNICA Show 2Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 2Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 3Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 4Environmental & Economic Factors Drives Global Demand for Pharmaceutical leak Testing and Deblistering 2Environmental & Economic Factors Drives Global Demand for Pharmaceutical leak Testing and Deblistering 3
(Date:8/12/2015)... 12, 2015 As the digital ... innovation and advanced biometrics technology is accelerating beyond expectations.  ... rely on using their credit cards, the digital currency, ... for payment services led by companies in the space ... Google, Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ...
(Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ...
(Date:8/10/2015)... Germany , August 10, 2015 ... in Eye Tracking Technology for more than two decades, ... Platform for integration into all consumer display formats. The ... seamless integration of eye tracking into consumer tablets, laptops, ... reality smart glasses. Omnivision,s leading sensor technology contributes to ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... LyondellBasell announced the following schedule and contact information for a teleconference on financial results through the ... , Monday, August 16, 2010 , ... Doug Pike, Vice President, Investor Relations , ... 800-369-1176 , London: 0800-279-9630 , ...
... Georgia Institute of Technology are using funding from the ... as ARPA-E to pursue two different, but related, ... of coal-burning power plants. Power plants ... the United States each year. The researchers will ...
... URBANA A dog,s indiscriminate taste is not always ... gastrointestinal infections and consequent ailments such as diarrhea and ... gastrointestinal diseases such as inflammatory bowel diseases that are ... by intestinal bacteria. Researchers at the University ...
Cached Biology News:Teleconference Alert: LyondellBasell Reviews Second Quarter 2010 Financial Results 2ARPA-E funding supports research on carbon dioxide removal from flue gases 2ARPA-E funding supports research on carbon dioxide removal from flue gases 3ARPA-E funding supports research on carbon dioxide removal from flue gases 4Illinois researchers use pyrosequencing to study canine intestinal bacteria 2
PlusOne EDTA, disodium salt, 100 g. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Buffers....
Normal human serum collected off the clot from healthy normal humans. Each donor unit is negative for anti-HIV 1&2, HIV-Ag, HCV, and HBsAg by FDA required tests...
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
Recombinant Mouse MMP-9, CF...
Biology Products: